We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+7.31%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$22.3M
AUM Growth
-$66.3M
Cap. Flow
-$67.3M
Cap. Flow %
-301.33%
Top 10 Hldgs %
97.68%
Holding
15
New
–
Increased
4
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
AGRX
Agile Therapeutics
AGRX
+$1.38M
2
PFX icon
PhenixFIN
PFX
+$18.1K
3
ACSF
American Capital Senior Floating, Ltd.
ACSF
+$11.7K
4
GARS
Garrison Capital Inc.
GARS
+$9.29K

Top Sells

Rank Stock Value
1
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$67.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.12M
3
ICMB icon
Investcorp Credit Management BDC
ICMB
+$160K
4
SCM icon
Stellus Capital Investment Corp
SCM
+$62.1K
5
CDTX
Cidara Therapeutics
CDTX
+$4.39K

Sector Composition

Rank Sector Weight
1 Healthcare 31.64%
2 Financials 8.56%
3 Industrials 2.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
1
DELISTED
Agile Therapeutics
AGRX
$12.4M 55.46%
887
+97
+12% +$1.38M
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.6B
$6.42M 28.77%
506,738
-115,281
-19% -$1.12M
BRK.B icon
3
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.29M 5.79%
8,945
– –
CSW
4
CSW Industrials
CSW
$4.91B
$364K 1.63%
11,253
– –
SCM icon
5
Stellus Capital Investment Corp
SCM
$243M
$262K 1.17%
24,103
-5,625
-19% -$62.1K
PRTK
6
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$246K 1.1%
18,909
– –
DOV icon
7
Dover
DOV
$29.3B
$237K 1.06%
3,991
– –
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$211K 0.94%
921
-19
-2% -$4.39K
PFX icon
9
PhenixFIN
PFX
$80.3M
$209K 0.94%
1,368
+122
+10% +$18.1K
SBBP
10
DELISTED
Strongbridge Biopharma plc.
SBBP
$184K 0.82%
35,245
-732
-2% -$3.3K
ACSF
11
DELISTED
American Capital Senior Floating, Ltd.
ACSF
$180K 0.81%
16,339
+1,084
+7% +$11.7K
GARS
12
DELISTED
Garrison Capital Inc.
GARS
$162K 0.73%
15,995
+891
+6% +$9.29K
ICMB icon
13
Investcorp Credit Management BDC
ICMB
$12.4M
$149K 0.67%
16,524
-16,956
-51% -$160K
MDGL icon
14
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$26K 0.12%
2,057
– –
CPXX
15
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-2,232,272
Closed -$67.4M

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2016 Portfolio in Review

As of Q3 2016, Caxton Corporation held 15 positions worth $22.3M, down 75% from $88.6M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caxton Corporation withdrew a net $67.3M in Q3 2016, closing 1 position and reducing 5 holdings. Its most notable exit was CELATOR PHARMACEUTICALS INC. COMMON STOCK, an estimated $67.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 7.1% a quarter earlier, followed by Financials and Industrials.

Against the trend, Caxton Corporation added an estimated $1.38M to Agile Therapeutics.

  • Caxton Corporation added most to Agile Therapeutics in Q3 2016, an estimated $1.38M increase.
  • Caxton Corporation's biggest Q3 2016 reduction was Madrigal Pharmaceuticals, cutting an estimated $1.12M.
  • Caxton Corporation fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q3 2016, selling an estimated $67.4M.
  • Caxton Corporation's ten largest holdings make up 98% of its $22.3M portfolio in Q3 2016.
  • Caxton Corporation opened 0 new positions and closed 1 in Q3 2016.
  • Caxton Corporation's portfolio value fell 75% quarter-over-quarter to $22.3M.

Based on Caxton Corporation's 13F filing for Q3 2016, filed 14 Nov 2016.